FlandersBio on Twitter

Galapagos NV: business update: http://t.co/6w1jppWE

posted 6 days ago

Follow us on Twitter

News

Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

ThromboGenics Raises € 0.6 Million from the Exercise of Warrants

26/03/2010

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, today announces that it has raised € 0.6 million as the result of the exercise of warrants by a number of the Company’s employees.

The 96.667 shares created as a result of this warrant exercise are now listed on Euronext Brussels. Following this transaction, ThromboGenics now has 29.156.234 shares outstanding.

Source: ThromboGenics

Tags: stock market

Filter by Tags

financing research stock market clinical trials merger or acquisition collaborations new products management awards infrastructure legal alliances regulatory new company medical biotech medtech industrial biotech plant biotech gmo bioenergy

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Archive

Back to top

Print